The stock was trading at its lowest level since April 2020. At 09:30 am; Biocon was quoting 2 per cent lower at Rs 303 vs a 1.2 per cent decline in the Sensex benchmark index. In the past three months, it has underperformed the market by falling 10 per cent as compared to a 5 per cent rally in the Sensex.
The US Food and Drug Administration (US-FDA) conducted three on-site inspections at Biocon Biologics’ (company's subsidiary) seven manufacturing facilities spanning two sites in Bengaluru, India and one at Johor, Malaysia. These inspections started with the Bengaluru site on August 11, 2022 and concluded with the Malaysia site on August 30, 2022.
These inspections were initiated on account of three preapproval inspections for biosimilar Bevacizumab, rh-Insulin and Insulin Aspart and a capacity expansion inspection for biosimilar Trastuzumab. These included multiple drug substance and drug product facilities and other support infrastructure at these sites.
Biocon said that the company does not expect the outcome of these inspections to impact the current supply of its products.
The observations primarily relate to the need for improving strategies for microbial control, enhancing quality oversight, augmenting the use of software applications & computerized tools to aid risk assessment & investigations and other procedural & facility upgrades, the company said.
“We will submit Corrective and Preventive Action Plans (CAPA), to the US FDA in the stipulated time frame,” Biocon said.
Biocon’s launches of bBevacizumab, bAspart and bAdalimumab, especially in the US, are expected to contribute to the near term growth of the business. With two strategic agreements signed with Serum and Viatris, Biocon is targeting revenues of $ 1.8 billion in FY24.
“We believe timely regulatory clearance and subsequent launch timeline, notably for expected FY23 launches of bAspart (CRL in September,2021) and bBevacizumab remain keys near term triggers for the company,” ICICI Securities said in a note.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app